Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity

被引:7
|
作者
Gong, Grace Q. [1 ,2 ]
Kendall, Jackie D. [2 ,3 ]
Dickson, James M. J. [2 ,4 ]
Rewcastle, Gordon W. [2 ,3 ]
Buchanan, Christina M. [1 ,2 ]
Denny, William A. [2 ,3 ]
Shepherd, Peter R. [1 ,2 ,3 ]
Flanagan, Jack U. [2 ,3 ,5 ]
机构
[1] Univ Auckland, Dept Mol Med, Auckland, New Zealand
[2] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
[3] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[4] Univ Auckland, Sch Biol Sci, Auckland, New Zealand
[5] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland, New Zealand
关键词
PHOSPHOINOSITIDE 3-KINASE GAMMA; NONCONSERVED AMINO-ACIDS; KINASE ALPHA INHIBITORS; PROTEIN-LIGAND DOCKING; ISOFORM SELECTIVITY; STRUCTURAL BASIS; WATER-MOLECULES; CLINICAL-TRIALS; AKT ACTIVATION; BREAST-CANCER;
D O I
10.1042/BCJ20161098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are major regulators of many cellular functions, and hyperactivation of PI3K cell signalling pathways is a major target for anticancer drug discovery. PI3K alpha is the isoform most implicated in cancer, and our aim is to selectively inhibit this isoform, which may be more beneficial than concurrent inhibition of all Class I PI3Ks. We have used structure-guided design to merge high-selectivity and high-affinity characteristics found in existing compounds. Molecular docking, including the prediction of water-mediated interactions, was used to model interactions between the ligands and the PI3K alpha affinity pocket. Inhibition was tested using lipid kinase assays, and active compounds were tested for effects on PI3K cell signalling. The first-generation compounds synthesized had IC50 (half maximal inhibitory concentration) values >4 mu M for PI3K alpha yet were selective for PI3K alpha over the other Class I isoforms (beta, delta and gamma). The second-generation compounds explored were predicted to better engage the affinity pocket through direct and water-mediated interactions with the enzyme, and the IC50 values decreased by similar to 30-fold. Cell signalling analysis showed that some of the new PI3K alpha inhibitors were more active in the H1047R mutant bearing cell lines SK-OV-3 and T47D, compared with the E545K mutant harbouring MCF-7 cell line. In conclusion, we have used a structure-based design approach to combine features from two different compound classes to create new PI3K alpha-selective inhibitors. This provides new insights into the contribution of different chemical units and interactions with different parts of the active site to the selectivity and potency of PI3K alpha inhibitors.
引用
收藏
页码:2261 / 2276
页数:16
相关论文
共 50 条
  • [41] Development and safety of PI3K inhibitors in cancer
    Miaomiao Yu
    Jiajia Chen
    Zhifei Xu
    Bo Yang
    Qiaojun He
    Peihua Luo
    Hao Yan
    Xiaochun Yang
    Archives of Toxicology, 2023, 97 : 635 - 650
  • [42] Discovery of imidazopyridine and imidazopyridazine inhibitors of PI3K
    Han, Wooseok
    Pecchi, Sabina
    Burger, Matthew
    Lan, Jiong
    Smith, Aaron
    Knapp, Mark
    Huh, Kay
    De Menezes, Daniel Lopes
    Jansen, Johanna
    Merritt, Hanne
    Kaufman, Susan
    Voliva, Charles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [43] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [44] Modulation of mitochondrial apoptosis by PI3K inhibitors
    Fulda, Simone
    MITOCHONDRION, 2013, 13 (03) : 195 - 198
  • [45] Development of PI3Kα inhibitors for tumor therapy
    Jia, Wenqing
    Luo, Shuyu
    Guo, Han
    Kong, Dexin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (17): : 8587 - 8604
  • [46] PI3K pathway inhibitors approach junction
    Holmes, David
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (08) : 563 - 565
  • [47] Development and safety of PI3K inhibitors in cancer
    Yu, Miaomiao
    Chen, Jiajia
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    ARCHIVES OF TOXICOLOGY, 2023, 97 (03) : 635 - 650
  • [48] PI3K inhibitors in thrombosis and cardiovascular disease
    Durrant, Tom N.
    Hers, Ingeborg
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [49] Inhibitors of PI3Kβ as Potential Treatment for Cancer
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (09): : 815 - 816
  • [50] PI3K pathway inhibitors approach junction
    David Holmes
    Nature Reviews Drug Discovery, 2011, 10 : 563 - 564